MedTrace Logo

Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation

NCT01151761 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2016-07-29

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine progression-free survival at 12 months for stereotactic body radiotherapy (SBRT) and chemotherapy for unresectable hilar cholangiocarcinoma (CCA).

Conditions

Interventions

PROCEDURE

Stereotactic Body Radiotherapy

Standard of care

DRUG

Gemcitabine

100 mg/m2, IV

DRUG

Cisplatin

25 mg/m2, IV

DRUG

Carboplatin

AUC 2, based on Calvert formula, IV

DRUG

Capecitabine

1000 mg/m2, PO

DRUG

5FU

200 mg/m2

PROCEDURE

Liver transplantation

Sponsors & Collaborators

Principal Investigators

  • Daniel T Chang · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2012-04-30
Completion
2012-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01151761 on ClinicalTrials.gov